News & Information

Webinar will address the critical need, role and value of radiation therapy quality assurance in oncology drug studies that include current or prior radiation.

Radialogica and Perceptive Imaging will be hosting a webinar titled “The Critical Impact of Radiotherapy Quality Management and Imaging for Oncology Trials” on Friday, February 13^th, 2026 at 11:00 AM  EST.  The webinar will feature Dr. Cliff Robinson, Chief Medical Officer of Radialogica, and Dr. Oliver Bohnsack, VP Scientific & Medical Services and Head of Oncology at Perceptive Imaging.  Click here to register for the event.

The majority of oncology patients receive radiotherapy (RT) as part of their treatment.  In the context of pharmaceutical clinical trials, RT may be delivered as part of the study question or for other indications before or after study treatment. Notably, significant variability exists in how RT treatment is planned and delivered, which may have direct consequences on tumor control, toxicity, and ultimately the outcome of clinical trials. Historically, pharmaceutical studies have not controlled for the impact of RT, leaving open the potential to bias outcomes in either direction regarding tumor response and tolerability. 

Fortunately, RT plans may be readily captured and analyzed using standardized file formats (DICOM-RT) which allows for objective assessment of targets and organs at risk. Such data may be objectively evaluated to assess RT quality, including likelihood of tumor control and toxicity, as well as providing a blueprint for subsequent evaluation of post-treatment imaging. The rigor and timeliness of RT quality assessment can be customized to meet the needs of the sponsor based on trial design, ranging from rapid review of plans prior to study treatment to passive capture of DICOM-RT data for subsequent secondary analyses, and multiple variations within.

This webinar will demonstrate how Perceptive Imaging and Radialogica are closing a critical gap in oncology trials by ensuring radiotherapy quality in the context of centralized imaging, which drives more accurate treatment decisions and preserves trial integrity.

Key topics include:

– The impact radiation can have on clinical trial outcomes (ex: a clinical trial may have subjects progressing too early, not because of a failed treatment but merely because of the radiation delivered previously.)

– Differentiating between expected Radiation Induced Lung Injury (RILI) changes versus tumor progression

– Quantifying RILI in relation to time elapsed since radiation

– How Perceptive and Radialogica work together to overcome variability in radiotherapy and deliver more reliable and robust imaging data for oncology clinical trials